Strong Q2 For Cipla Amid Waning Generic Nexium Impact
This article was originally published in PharmAsia News
Executive Summary
Cipla has reported robust growth in the second quarter, buoyed by one-off revenues from the US, but the Indian company sought to temper full-year top-line expectations in view of the strong first-half showing.
You may also be interested in...
Aurobindo-Sandoz End $1bn US Deal
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda Gets New India Chief, Mandate To Broaden Access
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
COVID-19, Lockdown Affect Trials in India But Coping Efforts In Hand
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.
Need a specific report? 1000+ reports available
Buy Reports